The Trump administration is delaying a pilot program where Medicare would cover the costs of GLP-1 weight-loss drugs, such as Wegovy and Zepbound, after major insurers declined to participate.
President Donald Trump has mentioned on a few occasions the popularity of weight-loss drugs, or as he refers to them, “fat shot.”